• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cardiol Therapeutics Inc (TSX: CRDL )

    2.660 +0.050 (+1.92%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 47,020
    Open 2.630
    Bid (Size) 2.640 (617)
    Ask (Size) 2.660 (1)
    Prev. Close 2.610
    Today's Range 2.580 - 2.670
    52wk Range 1.020 - 4.260
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
    Via AB Newswire
    Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
    In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
    Via TheNewswire.com
    Exposures Product Safety

    Performance

    YTD
    +123.53%
    +123.53%
    1 Month
    +3.10%
    +3.10%
    3 Month
    -3.97%
    -3.97%
    6 Month
    -3.97%
    -3.97%
    1 Year
    +131.30%
    +131.30%

    More News

    Read More
    Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
    Via News Direct
    Exposures Product Safety
    Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
    Via Newsfile
    Sector Spotlight: Orphan Drug Developers With Significant Upside
    Via AB Newswire
    Topics ETFs
    Exposures Product Safety
    Sector Spotlight: Orphan Drug Developers With Significant Upside
    Via TheNewswire.com
    Topics ETFs
    Exposures Product Safety
    Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
    Via AB Newswire
    Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
    Via News Direct
    Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
    Via Newsfile
    Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
    Via Newsfile
    Exposures Product Safety
    Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
    Via Newsfile
    CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
    Via Benzinga
    Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
    Via Newsfile
    Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
    Via AB Newswire
    Topics Stocks
    Exposures US Equities
    Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
    Via AB Newswire
    Topics Death
    Exposures Death Product Safety
    Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
    Via Newsfile
    Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
    Via Newsfile
    Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
    Via FinancialNewsMedia
    Exposures COVID-19 Product Safety
    Air Pollution is a Global Heart and Lung Health Concern
    Via FinancialNewsMedia
    Topics Climate Change Emissions Energy
    Exposures Climate Fossil Fuels
    The Healthcare Companies Fighting the World’s Biggest Killers
    Via FinancialNewsMedia
    Tackling Recurring Health Conditions Offers Hope to Patients
    Via FinancialNewsMedia
    As Health Problems Mount Patients Welcome New Treatments
    Via FinancialNewsMedia
    Breakthroughs In Treating Killer Diseases Could Lengthen Life
    Via FinancialNewsMedia
    Topics Death
    Exposures Death
    Market Movers. Today’s Top Stock Picks For New & Trending Opportunities
    From Stockhouse Publishing
    Via AccessWire
    Why Orphan Drug Designation Offers Several Benefits
    Via FinancialNewsMedia
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.